Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128622) titled 'A real-world prospective, multicenter clinical study of furmonertinib in the adjuvant treatment of stage IA2-IIIA EGFR mutation-positive non-small cell lung cancer after surgery' on July 23.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: The Fourth Hospital of Hebei Medical University

Condition: Non-Small Cell Lung Cancer

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-08-01

Target Sample Size: Observation group:300;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=334116

Disclaimer: Curated by...